Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Probiotics daily
Xiyuan Hospital of China Academy of Chinese Medical Sciences
SARS-CoV-2
1 trial -
Propofol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastroscopy
1 trial -
Propranolol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Portal Hypertension
1 trial -
Propranolol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Retinopathy of Prematurity
1 trial -
Propranolol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhoses
1 trial -
Pulsed dye laser (PDL)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Port Wine Stain
1 trial -
QFR
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
Raman spectrum
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Recombinant COVID-19 Vaccine (Sf9 Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
Reduction CTVp1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Ringer's solution acetate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholecystolithiasis and Thyroid Nodule
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenic Purpura
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventricular Mural Thrombosis
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhosis
1 trial -
Ropivacaine Hydrochloride 10 MG/ML [Naropin]
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
S-ketamine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anesthesia
1 trial -
SCOUT-Assisted Review Workflow
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease (CHD)
1 trial -
SGLT2 inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Kidney Transplantation
1 trial -
SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Major Depressive Disorder
1 trial -
Salvianolic Acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stroke
1 trial -
Sarcosine Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Parkinson's Disease With Dementia
1 trial -
Sertraline plus placebo of JWXYJN
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Depressive Disorder
1 trial -
Sheng-Yu-Tang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Leukemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources